Onward Medical N.V., a medical technology company, focuses on developing therapies for spinal cord injuries in the Netherlands and internationally. The company engages in developing ARCEX, an external non-invasive platform that consists of a wearable stimulator and wireless programmer, which restores or enhances physical movement of hand and arm function to people with spinal cord therapy; and ARCIM, an implantable platform, which consists of an implantable pulse generator and lead that is placed near the spinal cord that enables long-paralyzed people to stand and walk again with little or no assistance. It also engages in developing Up-LIFT Trial to evaluate the safety and effectiveness of ARCEX Therapy in restoring strength and function of upper extremities in people with spinal cord injury. Onward Medical N.V. was founded in 2014 and is headquartered in Eindhoven, Netherlands.

Onward Medical N.V.

ONWARD Medical is a medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injuries. ONWARD Medical’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ARC Therapy, which can be delivered by implantable (ARC-IM) or external (ARC-EX) systems, is designed to deliver targeted, programmed spinal cord stimulation to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life. 

ONWARD Medical has received nine Breakthrough Device Designations from the U.S. FDA encompassing both ARC-IM and ARC-EX. ARC-EX is an external, non-invasive platform consisting of a wearable stimulator and wireless programmer. Positive top-line data were reported in September 2022 from the company’s first pivotal study, called Up-LIFT, evaluating the ability of transcutaneous ARC Therapy to improve upper extremity strength and function. The company is now preparing marketing approval submissions for the U.S. and Europe. ARC-IM consists of an implantable pulse generator and lead placed near the spinal cord. The Company completed its first-in-human use of the ARC-IM neurostimulator in May 2022. 

ONWARD Medical is headquartered in Eindhoven, the Netherlands. It maintains a Science and Engineering Center in Lausanne, Switzerland, and has a growing US presence in Boston, Massachusetts. The Company has an academic partnership with .NeuroRestore, a collaboration between the Swiss Federal Institute of Technology (EPFL) and Lausanne University Hospital (CHUV). 

ONWARD

🎉 Congratulations to our Vice President, Clinical, Regulatory, & Quality, Dr. Erika Ross Ellison, for her recent election as President of the Institute of Electrical and Electronics Engineers IEEE Engineering in Medicine and Biology Society (EMBS), the world’s largest international society of biomedical engineers. 
 
We proudly celebrate Erika’s historic achievement. Her election marks the first time in the 72-year history of IEEE EMBS that a leader from industry will serve in this volunteer position. Erika will be the 7th woman in the society’s history to lead the organization. 
 
IEEE EMBS is driven by a mission to create innovations in healthcare technology for the benefit of all humanity. The group’s 12,000 members span 97 countries and include #researchers, #educators, #engineers and #clinicans. Their areas of expertise run wide and deep, including medical technology, #bioinformatics, #biotechnology, #robots. Many are also focused on the translation of science to clinical practice.  
 
We also celebrate this moment as an opportunity to further collaborate across the intersection of health and technology. As a company dedicated to developing groundbreaking solutions to serve the spinal cord injury (SCI) Community, having visibility and access to the most cutting-edge resources and talent is a true honor.  
 
Way to go, Erika! 🎉 
 
*All ONWARD Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.

#EmpoweringMovement #SCI

Looking forward to participating in BioCapital Europe in Amsterdam TODAY! 

The event, one of Europe’s leading life sciences investor conferences, is organized by venture capital fund EQT Group, an investor in our company.

During the conference, CEO Dave Marver will present and participate in 1:1 and group meetings with investors to discuss the Company’s leadership in neuroscience, including the use of our investigational ONWARD ARC-IM® Therapy paired with brain-computer interface (BCI) technology.  
  
Tickets are sold out, but we encourage you to watch the livestream by clicking on the link below to learn more about the latest advances in #medtech, #therapeutics, and #neuroscience. Don’t miss our presentation at 11:20 am CET today. 
 
#EmpoweringMovement #SCI #Innovation #BioCapitalEurope
 
*All ONWARD Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.
 
https://lnkd.in/gJNc-2qG


“There is no protocol for this. You must figure it out every day...” 
 
Kevin Babington, a former Olympian and equestrian champion with an SCI, and his wife Dianna recently shared a glimpse into their daily lives with our ONWARD team. Kevin had just experienced a medical setback and the resulting emotions were clear in our candid conversation about the struggles for people living with spinal cord injury.
 
Dianna openly shared how their lives have changed since Kevin’s injury during the 2019 Hampton Classic Horse Show. “There is no more cuddling on the couch, no spontaneous trips…it is everyday grinding, even with all the support that we have found within our community.” Dianna’s testimony was gripping and demonstrated a deep vulnerability that both moved and motivated us. 
 
Despite their challenges, Kevin and Dianna are optimistic things will get better and said they are cheering for companies like ONWARD that are dedicated to making new solutions a reality. Read more about the Babington’s work to bring hope to other equestrians with SCI through the The Kevin Babington Foundation.
 
*All ONWARD devices and therapies, including but not limited to ARC-IM®, ARC-EX®, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.
 
#EmpoweringMovement #SCI

✨ Thanks to De 7, the podcast from Belgian newspaper De Tijd, for its deep dive on brain-computer interface (BCI) technology. The episode, which was in Dutch, examined the buzz behind last week’s news about Neuralink’s first human implant, what it means, and the opportunities for investors. 
 
The show also laid out the events leading up to the news, and noted “this is not a first, the Dutch company ONWARD already implanted one [BCI] several years ago.” 

Education around new scientific breakthroughs is vital to continue progress and prevent misinformation. We appreciate journalists who help the public learn more about this groundbreaking investigational technology that has the potential to be used in combination with our investigational ARC Therapy™ to improve the lives of those with spinal cord injuries or other movement disorders. 

*All ONWARD devices and therapies, including but not limited to ARC-IM®, ARC-EX®, and ARC Therapy, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use. 

#EmpoweringMovement #BCI #SCI

It was a pleasure to participate in the Degroof Petercam Healthcare Conference this month, where our CEO Dave Marver updated attendees on our progress to launch ARC-EX® later this year. 
 
Thank you to all who joined us. You are critical for our mission to provide innovative solutions to restore movement, function, and independence after spinal cord injury (SCI).

*All ONWARD devices and therapies, including but not limited to ARC-IM®, ARC-EX, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.
  
#EmpoweringMovement #SCI #Investors

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue		554K -	800K 44.40%			500K -
cost of revenue	1.04M -	838K 19.50%	2.31M 175.54%	4.05M 75.27%	14.69M 262.91%
gross profit	-1.04M -	-284K 72.72%	-1.51M 431.34%	-4.05M 168.19%	-14.69M 262.91%	500K 103.40%
selling and marketing expenses	98K -	261K 166.33%	394K 50.96%	1.52M 284.77%	1.95M 28.69%
general and administrative expenses	1.25M -	2.25M 80.34%	2.67M 18.87%	6.24M 133.66%	8.07M 29.34%
selling general and administrative expenses	1.34M -	2.51M 86.61%	3.06M 22.21%	7.76M 153.08%	10.02M 29.21%
research and development expenses	4.72M -	5.36M 13.43%	5.82M 8.72%	7.93M 36.22%
other expenses	1.30M -	2.07M 59.48%	4.32M 108.50%	8.80M 103.80%	7.32M 16.80%	-36M 591.94%
cost and expenses	8.40M -	10.77M 28.16%	15.51M 44.01%	28.53M 83.92%	32.03M 12.25%	36M 12.40%
operating expenses	7.36M -	9.93M 34.90%	13.20M 32.92%	24.48M 85.44%	17.34M 29.18%	36M 107.60%
interest expense	1.49M -	2.67M 79.62%	4.43M 65.86%	5.60M 26.34%	1.51M 72.93%	600K 60.40%
ebitda	-8.17M -	-10.54M 29.01%	-15.29M 45.04%	-28.32M 85.18%	-31.29M 10.48%	-34.80M 11.22%
operating income	-8.40M -	-10.77M 28.16%	-15.51M 44.00%	-28.53M 83.94%	-32.03M 12.25%	-35.50M 10.84%
depreciation and amortization	234K -	228K 2.56%	219K 3.95%	213K 2.74%	740K 247.42%	700K 5.41%
total other income expenses net	-1.49M -	-2.67M 79.45%	-4.48M 67.74%	-5.71M 27.47%	-1.51M 73.57%	-1.30M 13.91%
income before tax	-9.89M -	-13.44M 35.88%	-19.99M 48.72%	-34.24M 71.28%	-33.54M 2.06%	-36.80M 9.73%
income tax expense	18K -	39K 116.67%	20K 48.72%	69K 245.00%	-766K 1,210.14%	100K 113.05%
net income	-9.91M -	-13.48M 36.03%	-20.01M 48.44%	-34.31M 71.45%	-32.77M 4.49%	-36.20M 10.46%
weighted average shs out	5.90M -	5.90M 0%	5.90M 0%	9.48M 60.76%	30.18M 218.23%
weighted average shs out dil	5.90M -	5.90M 0%	5.90M 0%	9.48M 60.76%	30.18M 218.23%
eps	-1.68 -	-2.29 36.31%	-3.39 48.03%	-3.62 6.78%	-1.09 69.89%	-1.20 10.09%
epsdiluted	-1.68 -	-2.29 36.31%	-3.39 48.03%	-3.62 6.78%	-1.09 69.89%	-1.20 10.09%

COM:ONWD

Wuhan Donglisheng M&E Technology Co., LTD

Last Close

4.66

22/11 16:35

Market Cap

179.38M

Beta: -

Volume Today

59.94K

Avg: -

Preview